The Prolia® Patient
Who is affected by osteoporosis in Canada?
Early detection
Osteoporosis in Canada
Many women and men will suffer from osteoporosis in their lifetime. Early detection and appropriate therapy are important.1
There are two similar tools available to Canadian physicians for estimating patients' 10-year fracture risk. The first is the updated tool of the Canadian Association of Radiologists and Osteoporosis Canada (CAROC). The second is the Canadian Fracture Risk Assessment tool from the World Health Organization (WHO) (FRAX). Both tools are available at osteoporosis.ca in the Healthcare Providers section under Tools.
These tools use the bone mineral density or T-score for the femoral neck only. They have been calibrated using the same Canadian fracture data and have been directly validated in Canadians.1
Consider Prolia for your osteoporosis patients at high risk for fracture
Prolia (denosumab injection) is indicated:2
- for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral and hip fractures.
- as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
- as a treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT), who are at high risk for fracture.
- as a treatment to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AI) therapy, who have low bone mass and are at high risk for fracture.
- as a treatment to increase bone mass in women and men at high risk for fracture due to sustained systemic glucocorticoid therapy.
- as a treatment to increase bone mass in women and men at high risk for fracture who are starting or have recently started long-term glucocorticoid therapy.
Access the 2010 Osteoporosis Clinical Practice Guidelines in the virtual library.
Virtual Library
* The correlation between increased bone density and reduction of bone fracture in men with osteoporosis has not been established.
References
| 1. | Papaioannou A, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-67. |
| 2. | Prolia (denosumab injection) Product Monograph. Amgen Canada Inc., November 24, 2023.. |
